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a b s t r a c t
Left ventricular active ﬁxation lead is fundamental for targeted pacing site. The challenge is
the extraction but in our experience Attain® StabilityTM was removed without any problem.
As usual the lead can cause a thrombosis of the coronary vein but we performed a venoplasty
in order to place again a lead in the target site and maintain the CRT response.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Targeted pacing site is fundamental in cardiac resynchroniza-
tion therapy to achieve reverse left ventricular (LV) remodel-
ing.1,2 The recently released active ﬁxation LV lead Attain®
StabilityTM (Model 20066, Medtronic Inc, Maastricht, the
Netherlands) enables a targeted pacing site at no compromise
with the risk of lead dislodgement3,4 or phrenic nerve
stimulation, and with an acceptable LV pacing threshold3
regardless of vein length and size.4 The challenge for the active
ﬁxation lead is the feasibility of extraction, given the former
experience with the deployable-lobes Starﬁx lead (Medtronic
Inc., Minneapolis, MN). The Attain® StabilityTM features a side
helix as ﬁxation mechanism, which has proven easy to be
extracted in the experimental model. We report a case where
LV extraction occurred about 7 months after implantation
because of pocket infection.* Corresponding author.
E-mail address: matteo.ziacchi@gmail.com (M. Ziacchi).
http://dx.doi.org/10.1016/j.ihj.2015.10.379
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier2. Case report
An 83-year-old woman had recurrent hospital admissions
along 3 years with severe congestive heart failure (NYHA III to
IV) due to idiopathic dilated cardiomyopathy, permanent
atrial ﬁbrillation, wide QRS (160 ms) with complete left bundle
branch block morphology, and severe left ventricular dys-
function (LV ejection fraction = 27%). The patient was suc-
cessfully implanted with CRT-P (Consulta, Medtronic,
Minneapolis, MN) with a 5076 CapSureFix Novus Lead in
right ventricle and an active ﬁxation left ventricular lead in a
mid-part of a postero-lateral vein of the coronary sinus
(Attain® StabilityTM Model 20066 LV lead; Medtronic, Inc,
Tilburg, the Netherlands) that matched with the target pacing
site as observed by pre-operative strain analysis at echocar-
diography. This target pacing site was concordant with
the intraoperative Q-LV measurement, LV depolarization B.V. All rights reserved.
Fig. 1 – Attain® StabilityTM lead before the implant and after the extraction.
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ventricular node ablation was performed concomitantly
during the procedure because of a very difﬁcult rate control
with drugs (resting heart rate > 70 bpm on metoprolol
+ diltiazem with symptomatic hypotension); only metoprolol
50 mg daily was given at follow-up.Fig. 2 – Re-implantation of a new Attain® StabilityTM lead. Legen
venoplasty with multiple balloon inflations starting from the dis
coronary sinus (B), coronary sinus angiogram after the venoplasThe patient had clinical improvement and diuretics were
gradually decreased. Seven months after CRT-P implantation,
the patient showed fever (37.8 8C) and an inﬂammatory skin
reaction at the pacemaker pocket. Laboratory: white blood
cells 4400/mmc, red blood cells 3,960,000/mmc, platelet
147,000/mL, C-reactive protein mildly increased at 1.45 mg/dl,ds: coronary sinus angiogram after lead extraction (A),
tal portion of the coronary vein up to its take-off from the
ty (C), Attain® StabilityTM lead final placement (D).
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were detected on the leads; the patient was a CRT super-
responder based on normalization of left ventricular volume
(50% reduction of end systolic volume) and of LV ejection
fraction (increased to 60%). Positron emission tomography
(PET) scan was highly suggestive of pocket inﬂammation/
infection (SUV max = 8.9), and showed no abnormal ﬁndings
endovascular and at other sites. Skin thinning and reddening
progressed over one week.
Empirical antibiotic therapy against staphylococci was
started with i.v. vancomycin and rifampicin and the fever
subsided. After 3 days, the CRT-P system was explanted from
the left side. The active ﬁxation lead was removed as per the
manufacturer's recommended technique without any prob-
lem: after insertion of a regular stylet, the lead was turned
counter-clockwise (around 8–10 turns) and then traction was
applied with a mild force (same force needed as with others
left ventricular passive leads, close to the 0.5–1 kg as
mentioned in the training). On visual examination, the ﬁxation
helix appeared elongated (Fig. 1). The patient was nearly
pacemaker-dependent with an escape rhythm at 30 bpm, so a
new CRT-P system was implanted right-sided. Owing to a
nearly complete thrombosis of the coronary vein previously
hosting the LV lead, venoplasty with repeated inﬂations of a
4 mm  8 mm balloon was performed, in order to place again
the LV lead at the same target site and maintain the CRT super-
response (Fig. 2A–D). A new Attain® StabilityTM was implanted
with good electrical parameters. The culture of the explanted
device revealed Staphylococcus aureus infection; hence, the
patient was treated with i.v. vancomycin and oral rifampicin
for 4 weeks. Neither fever nor pocket infection was observed
during 6 months follow-up.
All electrical parameters of pacemaker were regular (right
ventricular and LV sensing respectively 11.5 mV and 6.8 mV,
with capture threshold respectively 0.3 V and 1.5 V and
impedance was respectively 471 V and 839 V).
3. Discussion
The possibility to target an LV stimulation site regardless of
vein length and size is a great opportunity to increase the
chances of response to CRT, and to prevent lead dislodgement
and phrenic stimulation. The design of the Attain® StabilityTM
allows an easy disengagement at the ‘‘distal’’ level (the target
vein), owing to the different conception compared to the
Starﬁx lead. Stabilization with lead stenting has also proved
effective and amenable to uncomplicated lead extraction.3,5
Though more data on long-implanted leads are awaited, the
grade of lead engagement along the thoracic veins course
cannot be anticipated as different from any other 4F LV lead.
Thus, we believe that this technological improvement should
enhance the adoption of active ﬁxation LV leads, the
perception of limited extractability being its major opponent
in the clinicians' opinion. In this patient, a targeted lead
placement was coupled to AV node ablation owing to a difﬁcultrate control during AF, as recommended in literature,6,7
resulting in a super-responder. The timing of re-implantation
after pocket infection was dictated by the risk of complete
coronary vein thrombosis at short term, that might have
precluded a successful lead re-implantation and CRT delivery,
as previously reported by Burke et al.8 in patients with
indwelling leads for longer than 3 months. Moreover, the
absence of endovascular infection (blood culture, PET, echo-
cardiography) supported an early re-implantation strategy.9
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